Overview

A Study of EDP-235 in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Enanta Pharmaceuticals